MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Inicio・Lista de Acciones・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Cerrado

SectorSalud

25.8 -2.09

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

25.73

Máximo

26.31

Métricas clave
By Trading Economics
Ingresos	23M 7.4M
Ventas	18M 99M
BPA	0.06
Margen de beneficio	7.468
Empleados	342
EBITDA	23M 11M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+19.76% upside

Dividendos
By Dow Jones
Próximas Ganancias	24 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	869M 3.3B
Apertura anterior	27.89
Cierre anterior	25.8

Noticias sobre sentimiento de mercado

By Acuity

50%

159 / 361 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

12.42 / 14.93 Soporte y Resistencia

Arcutis Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 ene 2026, 23:29 UTC

Acciones populares

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 ene 2026, 22:48 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 ene 2026, 22:43 UTC

Adquisiciones, fusiones, absorciones

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 ene 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 ene 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Auto & Transport Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 ene 2026, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 ene 2026, 21:48 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 ene 2026, 21:41 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 ene 2026, 21:38 UTC

Adquisiciones, fusiones, absorciones

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 ene 2026, 21:30 UTC

Adquisiciones, fusiones, absorciones

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 ene 2026, 20:44 UTC

Ganancias

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 ene 2026, 20:42 UTC

Charlas de Mercado

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 ene 2026, 20:28 UTC

Charlas de Mercado

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 ene 2026, 19:12 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 ene 2026, 18:53 UTC

Charlas de Mercado

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 ene 2026, 18:41 UTC

Charlas de Mercado

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 ene 2026, 18:31 UTC

Charlas de Mercado

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

16 ene 2026, 17:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

16 ene 2026, 17:03 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 ene 2026, 17:03 UTC

Charlas de Mercado

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 ene 2026, 16:32 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 ene 2026, 16:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Arcutis Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

19.76% repunte

Estimación a 12 meses

Media 31.57 USD 19.76%

Máximo 37 USD

Mínimo 29 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

12.42 / 14.93Soporte y Resistencia

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentimiento

By Acuity

159 / 361 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.